Made Sukmawati
Udayana University School of Medicine, Indonesia
Scientific Tracks Abstracts: J Neonatal Biol
Feeding intolerance is a common condition that affects preterm infants. Erythromycin is a prokinetic agent used to treat feeding intolerance, but its efficacy remains inconclusive. The objective of this study is to evaluate the effectiveness of oral erythromycin to enhance feeding tolerance in preterm infants. This prospective, randomized controlled trial in preterm infants was conducted at Sanglah Hospital from June 2015 to January 2016. Eligible infants were randomized to receive 12.5 mg/kg/ dose oral erythromycin or a placebo, every 8 hours. The primary outcome was the time to establish full enteral feeding. The secondary outcomes were body weight at full enteral feeding and length of hospital stay. Of 62 initial subjects, 3 infants dropped out of the study. Thirty infants were given erythromycin and 29 infants were given placebo. The baseline characteristics of the two groups were similar, with mean of gestational ages of 31.4 (SD 1.7) weeks in the erythromycin group and 32.4 (SD 2.2) weeks in the placebo group. The median times to reach full enteral feeding did not significantly differ between the two groups, with 10 (SD 5.3) days in the erythromycin group vs. 8 (SD 6.5) days in the placebo group (P=0.345). Also, median body weights at full enteral feeding and lengths of hospital stay were not significantly different between the two groups. As conclusion erythromycin of 12.5 mg/kg/dose every 8 hours as prophylactic treatment did not significantly enhance feeding tolerance in preterm infants. Median body weights at full enteral feeding and length of hospital stay were not significantly different between the erythromycin and placebo groups.
Sukmawati has completed her study in Neonatology Consultant in Indonesia University-Cipto Mangunkusumo Hospital, Jakarta, 2016. She is Neonatology Staff in Sanglah Hospital, Bali, until now.
Email:ukma_bali75@yahoo.co.id